alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
(logo) LNR

         Partners, LLC

 

 

ANNUAL STATEMENT OF COMPLIANCE

 

OF

 

LNR PARTNERS, LLC

** **

** **

The undersigned, Job Warshaw,being the President of LNR Partners, LLC (the "Special Servicer"), asspecial servicer under the applicable Pooling and Servicing Agreement for thetransactions listed on Schedule I hereto, hereby certifies, subject toany limitations listed on Schedule I hereto, as of the date hereof, onbehalf of the Special Servicer, solely in his capacity as an authorized officerof the Special Servicer and not in his individual capacity, as follows:

 

1. A review of the activitiesperformed by the Special Servicer during the period commencing on January 1,2016 and ending on December 31, 2016 (or any other shorter period set forth on ScheduleI hereto) (the "Reporting Period"), and the Special Servicer'sperformance under the Pooling and Servicing Agreement has been made under mysupervision; and

 

2. To the best of myknowledge, based on such review and using the applicable servicing criteriaunder Item 1122 of Regulation AB, the Special Servicer has fulfilled itsobligations under the applicable Pooling and Servicing Agreement in allmaterial respects throughout the Reporting Period.

 

 

LNR Partners, LLC, 

a Florida limited liabilitycompany

 

By: /s/ Job Warshaw

Job Warshaw

President

 

 

Dated: February 22, 2017

 

 

1601 Washington Avenue ∙Suite700 ∙ Miami Beach, Florida 33139-3164

Telephone: (305) 695-5600 ∙Fax: (305)695-5601

 

 

**Schedule I**

 

MSBAM 2015-C23

Morgan Stanley Bank of AmericaMerrill Lynch Trust 2015-C23, Commercial Mortgage Pass-Through Certificates,Series 2015-C23

 

Morgan Stanley Capital I Inc. 

1221 Avenue of the Americas 

New York NY 10020

James Y. Lee

 

Morgan Stanley Capital I Inc.

1585 Broadway

New York NY 10036 

Stephen Holmes

 

Pentalpha Surveillance LLC

375 N. French Road, Suite 100 

Amherst NY 14228 

Don Simon

 

Pentalpha Surveillance LLC 

Bass, Berry and Sims PLC

150 Third Avenue South, Suite2800

Nashville TN 37201

Jay H. Knight

 

Wells Fargo Bank, N.A. 

9062 Old Annapolis Road 

Columbia MD 21045 

Group Notices

 

Wells Fargo Bank, N.A. 

9062 Old Annapolis Road 

MAC: R1204-010 

Columbia MD 21045

Irene Kaplanis

 

Wilmington Trust, NationalAssociation 

1100 North Market Street 

Wilmington DE 19890

Dorri Costello

 

Wilmington Trust, NationalAssociation 

1100 North Market Street 

Wilmington DE 19890 

Group
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4690]


=======================================================================
-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Federal Open Market Committee; Domestic Policy Directive of 
January 26 and 27, 2010

    In accordance with Sec.  271.25 of its rules regarding availability 
of information (12 CFR part 271), there is set forth below the domestic 
policy directive issued by the Federal Open Market Committee at its 
meeting held on January 26 and 27, 2010.\1\
---------------------------------------------------------------------------

    \1\[thinsp]Copies of the Minutes of the Federal Open Market 
Committee at its meeting held on January 26 and 27, 2010, which 
includes the domestic policy directive issued at the meeting, are 
available upon request to the Board of Governors of the Federal 
Reserve System, Washington, D.C. 20551. The minutes are published in 
the Federal Reserve Bulletin and in the Board's annual report.
---------------------------------------------------------------------------

    The Federal Open Market Committee seeks monetary and financial 
conditions that will foster price stability and promote sustainable 
growth in output. To further its long-run objectives, the Committee 
seeks conditions in reserve markets consistent with federal funds 
trading in a range from 0 to \1/4\ percent. The Committee directs the 
Desk to purchase agency debt and agency MBS during the intermeeting 
period with the aim of providing support to private credit markets and 
economic activity. The timing and pace of these purchases should depend 
on conditions in the markets for such securities and on a broader 
assessment of private credit market conditions. The Desk is expected to 
execute purchases of about $175 billion in housing-related agency debt 
and about $1.25 trillion of agency MBS by the end of the first quarter. 
The Desk is expected to gradually slow the pace of these purchases as 
they near completion. The Committee anticipates that outright purchases 
of securities will cause the size of the Federal Reserve's balance 
sheet to expand significantly in coming months. The Committee directs 
the Desk to engage in dollar roll transactions as necessary to 
facilitate settlement of the Federal Reserve's agency MBS transactions 
to be conducted through the end of the first quarter, as directed 
above. The System Open Market Account Manager and the Secretary will 
keep the Committee informed of ongoing developments regarding the 
System's balance sheet that could affect the attainment over time of 
the Committee's objectives of maximum employment and price stability.
    By order of the Federal Open Market Committee, February 23, 2010.

Brian F. Madigan,
Secretary, Federal Open Market Committee.
[FR Doc. 2010-4690 Filed 3-4-10; 8:45 am]
BILLING CODE 6210-01-S
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 19-0660

STATE OF MONTANA,

Plaintiff and Appellee,

v.

ALVIAN ERREVY MARQUEZ,

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time, 

and good cause appearing,

IT IS HEREBY ORDERED that Appellant is granted an extension 

of time to and including May 1, 2020, within which to prepare, file, and 

serve Appellant’s opening brief on appeal.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

March 25 2020

03/25/2020

Case Number: DA 19-0660
§ 861.36 Effective dates. ( a ) A regulation establishing, amending, or revoking a performance standard will set forth the date upon which it will take effect. To the extent practical, consistent with the public health and safety, such effective date will be established so as to minimize economic loss to, and disruption or dislocation of, domestic and international trade.
( b ) Except as provided in paragraph (c) of this section, no regulation establishing, amending, or revoking a standard may take effect before 1 year after the date of its publication unless: ( 1 ) The Food and Drug Administration determines that an earlier effective date is necessary to protect the public health and safety; or
( 2 ) The standard has been established for a device that, by the effective date of the standard, has been reclassified from class III to class II.
( c ) The Food and Drug Administration may declare a proposed regulation amending a standard effective on publication in the Federal Register if it determines that making the regulation so effective is in the public interest. A proposed amendment of a performance standard made effective upon publication may not prohibit the introduction or delivery for introduction into interstate commerce of a device that conforms to the standard without the change or changes provided in the proposed amendment until the effective date of any final action on the proposal.
[45 FR 7484, Feb. 1, 1980, as amended at 57 FR 58405, Dec. 10, 1992]
§ 660.41 Processing. ( a ) *Method.* The processing method shall be one that has been shown to yield consistently a specific and potent final product, free of properties which would adversely affect the test results when the product is tested by the methods recommended by the manufacturer in the package insert. The product and all ancillary reagents and materials supplied in the package with the product shall be manufactured in a manner that will reduce the risk of transmitting type B viral hepatitis.
( b ) *Ancillary reagents and materials.* All ancillary reagents and materials supplied in the package with the product shall meet generally accepted standards of purity and quality and shall be effectively segregated and otherwise manufactured in a manner that will reduce the risk of contaminating the product and other biological products. Ancillary reagents and materials accompanying the product, which are used in the performance of the test as described by the manufacturer's recommended test procedures, shall have been shown not to affect adversely the product within the prescribed dating period.
( c ) *Final container.* A final container shall be sufficiently transparent to permit visual inspection of the contents for presence of particulate matter and increased turbidity. The effectiveness of the contents of a final container shall be maintained throughout its dating period.
( d ) *Date of manufacture.* The date of manufacture of Hepatitis B Surface Antigen that has been iodinated with radioactive iodine (125I) shall be the day of labeling the antibody with the radionuclide.
[44 FR 36382, June 22, 1979, as amended at 49 FR 1685, Jan. 13, 1984]
<PAGE>
                                   EXHIBIT 21
<PAGE>

                                   EXHIBIT 21

                         SUBSIDIARIES OF THE REGISTRANT


Parent

Harrodsburg First Financial Bancorp, Inc.
<TABLE>
<CAPTION>
                                                   Percentage           State of
Subsidiaries                                         Owned              Incorporation
------------                                         -----              -------------

<S>                                                <C>                  <C>
First Federal Savings Bank of Harrodsburg (a)      100%                 United States

Harrodsburg Savings and Loan                       100%                 Kentucky
  Service Corporation (a)

</TABLE>

-----------------
(a)      The  operations  of this  subsidiary  are included in the  consolidated
         financial   statements   contained   in  the  1996  Annual   Report  to
         Stockholders incorporated herein by reference.
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 13-31158

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff - Appellee

v.

MARCO DILLON,

Defendant - Appellant

Appeals from the United States District Court

for the Eastern District of Louisiana

USDC No. 2:12-CR-190

Before SMITH, BARKSDALE, and PRADO, Circuit Judges.

PER CURIAM:*

Marco Dillon was convicted for conspiracy to distribute, and to possess 

with the intent to distribute, 28 grams or more, but less than 280 grams, of 

cocaine base (crack), pursuant to 21 U.S.C. §§ 841(a)(1), (b)(1)(A) and 846. In 

challenging the conviction, Dillon claims the district court erred by admitting 

certain evidence as intrinsic to the charged conspiracy. (Dillon also claims the 

evidence is not admissible under Federal Rule of Evidence 404(b), concerning 

* Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5th Cir. 

R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

November 13, 2014

Lyle W. Cayce

Clerk

 

 Case: 13-31158 Document: 00512835652 Page: 1 Date Filed: 11/13/2014
No. 13-31158

extrinsic evidence. Because, as discussed below, the evidence was intrinsic, we 

need not reach this second issue.) 

Evidentiary rulings are reviewed for an abuse of discretion. United 

States v. Coleman, 78 F.3d 154, 156 (5th Cir. 1996) (citation omitted). During 

the time period of the charged conspiracy, Dillon sold crack cocaine to the same 

confidential informant who had previously purchased crack cocaine from two 

of Dillon’s co-conspirators. Dillon was also arrested for possession of a scale 

containing cocaine residue. The district court did not abuse its discretion by 

admitting the evidence as intrinsic because the contested evidence was 

relevant to establish the relationship between the co-conspirators and how the 

conspiracy was structured and operated. E.g., United States v. Wood, 58 F.3d 

637, 1995 WL 371100 at *5 (5th Cir. 1995) (unpublished but precedential 

pursuant to 5th Cir. R. 47.5.3); see also United States v. Watkins, 591 F.3d 780, 

784–85 (5th Cir. 2009). 

AFFIRMED.

2

 Case: 13-31158 Document: 00512835652 Page: 2 Date Filed: 11/13/2014
EXHIBIT 3.4

                            CERTIFICATE OF AMENDMENT
                                       TO
                              AMENDED AND RESTATED
                          CERTIFICATE OF INCORPORATION
                                       OF
                              SPORTSLINE USA, INC.


         SPORTSLINE USA, INC. (the "Corporation"), a corporation organized and
existing under and by virtue of the General Corporation Law of the State of
Delaware DOES HEREBY CERTIFY:

         FIRST: That Article I of the Amended and Restated Certificate of
Incorporation of the Corporation is hereby amended to read as follows:

         The name of the corporation is SportsLine.com, Inc. (hereinafter called
the "Company").

         SECOND: That said amendment was duly adopted and approved by the Board
of Directors and the stockholders of the Corporation entitled to vote thereon in
accordance with the applicable provisions of Section 242 of the General
Corporation Law of the State of Delaware.

         IN WITNESS WHEREOF, said Corporation has caused this Certificate be
signed by its duly authorized officer this 19th day of November, 1999.

                                            SPORTSLINE USA, INC.,
                                            a Delaware corporation


                                            /s/ Michael Levy
                                            -----------------------
                                            Michael Levy, President
**Exhibit 99.4**

 
|  | **•  ****Ernst & Young****LLP**220 South Sixth Street, Ste  1400  Minneapolis, MN 55402-4509 | •   Phone:  (612) 343-1000  www.ey.com |
|--|-----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|

 

Reportof Independent Registered Public Accounting Firm

 

TargetNational BankIts Officers and DirectorsAs Servicer

 

We haveexamined management’s assertion in the accompanying report, Report of  Management on Compliance, dated March 15,2007, that Target National Bank  (theBank), as Servicer, complied in all material respects with the administrationand  servicing requirements of ArticleIII, Article IV, and Section 8.8 of the Amended and  Restated Pooling and Servicing Agreement,dated April 28, 2000, and the applicable provisions of the Series 2002-1 Supplement, dated July 2, 2002, and theSeries 2005-1  Supplement, dated November9, 2005, to the Target Credit Card Master Trust, as set  forth in Exhibit A to the accompanying Reportof Management on Compliance as of  December30, 2006, and for the fiscal year then ended. The Bank’s management is  responsible for the Bank’s compliance withthose requirements. Our responsibility is to express an opinion on management’sassertion based on our examination.

 

Ourexamination was conducted in accordance with attestation standards establishedby  the Public Company Accounting OversightBoard (United States) and, accordingly,  includedexamining, on a test basis, evidence about the Bank’s compliance with those  requirements and performing such otherprocedures as we considered necessary in the circumstances. We believe that our examination provides a reasonablebasis for our  opinion. Our examinationdoes not provide a legal determination on the Bank’s 

compliancewith specified requirements.

 

In ouropinion, management’s assertion that the Bank complied with the aforementioned requirementsas of and for the year ended December 30, 2006, is fairly stated, in all materialrespects.

 
|   |   |  |
|--------|--------|--|

 

 

March 15, 2007

 

A Member Practice of Ernst & Young Global

 

----
Exhibit
      31.1








I,
      Mary
      G. Merritt, certify that:





1.
      I have
      reviewed this annual report on Form 10-KSB of Preferred Voice, Inc.;





2.
      Based
      on my knowledge, this annual report does not contain any untrue statement of
      a
      material fact or omit to state a material fact necessary to make the statements
      made, in light of the circumstances under which such statements were made,
      not
      misleading with respect to the period covered by this annual report;





3.
      Based
      on my knowledge, the financial statements, and other financial information
      included in this annual report, fairly present in all material respects the
      financial condition, results of operations and cash flows of the registrant
      as
      of, and for, the periods presented in this annual report.





4.
      I am
      responsible for establishing and maintaining disclosure controls and procedures
      (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
      I
      have:





a.
      designed such disclosure controls and procedures to ensure that material
      information relating to the registrant, including its consolidated subsidiaries,
      is made known to me by others within those entities, particularly during the
      period in which this annual report is being prepared;





b.
      evaluated the effectiveness of the registrant's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this annual
      report (the "Evaluation Date"); and





c.
      presented in this annual report my conclusions about the effectiveness of the
      disclosure controls and procedures based on my evaluation as of the Evaluation
      Date;





5.
      I have
      disclosed, based on our most recent evaluation, to the registrant's auditors
      and
      the audit committee of the registrant's board of directors (or persons
      performing the equivalent function):





a.
      all
      significant deficiencies in the design or operation of internal controls which
      could adversely affect the registrant's ability to record, process, summarize
      and report financial data and have identified for the registrant's auditors
      any
      material weaknesses in internal controls; and





b.
      any
      fraud, whether or not material, that involves management or other employees
      who
      have a significant role in the registrant's internal controls; and





6.
      I have
      indicated in this annual report whether or not there were significant changes
      in
      internal controls or in other factors that could significantly affect internal
      controls subsequent to the date of our most recent evaluation, including any
      corrective actions with regard to significant deficiencies and material
      weaknesses.







/s/
      Mary G. Merritt


Mary
      G.
      Merritt


Chief
      Financial Officer


(Principal
      Executive Officer


and
      Principal Financial Officer)


July
      14,
      2006
# C_2016402EN.01003201.xml

| 31.10.2016 | EN | Official Journal of the European Union | C 402/32 |
| --- | --- | --- | --- |

31.10.2016

EN

Official Journal of the European Union

C 402/32

---

Judgment of the General Court of 15 September 2016 — PT Ciliandra Perkasa v Council

(Case T-120/14) (1)

1

((Dumping - Imports of biodiesel originating in Indonesia - Definitive anti-dumping duty - Article 2(5) of Regulation (EC) No 1225/2009 - Normal value - Production costs))

(2016/C 402/35)

Language of the case: English

Parties

Parties

Applicant: PT Ciliandra Perkasa (Jakarta, Indonesia) (represented by: F. Graafsma and J. Cornelis, lawyers)

Applicant:

Defendant: Council of the European Union (represented initially by S. Boelaert, and subsequently by H. Marcos Fraile, acting as Agents, and by R. Bierwagen and C. Hipp, lawyers)

Defendant:

Interveners in support of the defendant: European Commission (represented by J.-F. Brakeland, M. França and A. Stobiecka-Kuik, acting as Agents) and European Biodiesel Board (EBB) (Brussels, Belgium) (represented by O. Prost and M.-S. Dibling, lawyers)

Interveners in support of the defendant:

Re:

Re:

Action pursuant to Article 263 TFUE for annulment of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia (OJ 2013 L 315, p. 2) in so far as it imposes an anti-dumping duty on the applicant.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Articles 1 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as it concerns PT Ciliandra Perkasa; |
| --- | --- |

1.

Annuls Articles 1 of Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia, in so far as it concerns PT Ciliandra Perkasa;

| 2. | Orders the Council of the European Union to bear its own costs and to pay the costs incurred by PT Ciliandra Perkasa; |
| --- | --- |

2.

Orders the Council of the European Union to bear its own costs and to pay the costs incurred by PT Ciliandra Perkasa;

| 3. | Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs. |
| --- | --- |

3.

Orders the European Commission and the European Biodiesel Board (EBB) to bear their own costs.

---

(1)  OJ C 112, 14.4.2014.

1

---
#### § 810.4 Service of orders.

Orders issued under this part will be served in person by a designated employee of FDA, or by certified or registered mail or similar mail delivery service with a return receipt record reflecting receipt, to the named person or designated agent at the named person's or designated agent's last known address in FDA's records.